MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
February 22, 2024 10:30 ET
|
MAIA Biotechnology, Inc.
Topline data expected in second half of 2024THIO-101 will be the first completed clinical study of a telomere targeting agent in the field of cancer drug discovery and treatment CHICAGO, IL, Feb. ...
Invectys Announces Initiation of Phase 1/2a Clinical Trial in Solid Tumors and Change in Leadership
July 13, 2023 09:08 ET
|
Invectys, Inc.
Houston, TX, USA, July 13, 2023 (GLOBE NEWSWIRE) -- Invectys, Inc., a clinical-stage immuno-oncology company developing novel therapies for the treatment of advanced cancers, today announces it has...
GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 15, 2023 17:00 ET
|
GT Biopharma, Inc.
Cash of approximately $19.9 million as of March 31, 2023, provides ample runway to fund operations into Q2 2024; anticipated to be sufficient to achieve IND clearance for GTB-3650 and GTB-5550, and...
GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
March 30, 2023 17:00 ET
|
GT Biopharma, Inc.
Proforma cash of approximately $23.0 million includes $16.5 million in cash as of December 31, 2022, plus $6.5 million in gross proceeds received from a registered direct offering priced at a premium...
GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
February 24, 2023 09:00 ET
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the...
GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities
February 02, 2023 09:46 ET
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market
December 30, 2022 08:00 ET
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer
December 14, 2022 07:30 ET
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
November 10, 2022 15:15 ET
|
GT Biopharma, Inc.
Poster #1: Tri-specific killer engagers target natural killer cells towards mesotheliomaPoster #2: Enhancing NK cell function in the 'cold' tumor microenvironment of prostate cancer with a novel...
GT Biopharma Announces Adjournment of Special Shareholders Meeting
October 04, 2022 16:10 ET
|
GT Biopharma, Inc.
- Meeting adjourned to October 10, 2022 at 11 a.m. PST- GTB encourages all stockholders of record on August 8, 2022 who have not yet voted- to do so by 11:59 p.m. PST Time on October 9, 2022 ...